TG THERAPEUTICS, INC.
TGTX evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Market Cap:
- $8.25B
- Lead Asset:
- Azer-cel (Phase 1)
What it means
What to watch
Prepared research question
What matters most for TGTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TGTX
TG Therapeutics, Inc. (TGTX) is a commercial-stage biopharmaceutical company focused on immunology and oncology, anchored by its approved multiple sclerosis therapy BRIUMVI (ublituximab-xiiy) and supported by a pipeline of early-stage assets.
Key risk: Over-reliance on BRIUMVI
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 8 pipeline candidates · 49 clinical trials · 1 catalyst · 1 FDA decision for TG THERAPEUTICS, INC..
TG Therapeutics, Inc. (TGTX) is a commercial-stage biopharmaceutical company focused on immunology and oncology, anchored by its approved multiple sclerosis therapy BRIUMVI (ublituximab-xiiy) and supported by a pipeline of early-stage assets.
- Cash & equivalents of $482.6M as of 2026-06-30 [sec]
- Total revenue of $240.3M and net income of $7.8M as of 2026-06-30 [sec]
- BRIUMVI (ublituximab-xiiy) is approved for relapsing forms of multiple sclerosis and has captured more than one-third of the IV anti-CD20 market as of 2026-09-18 [news]
- Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia initiated July 2026 [news]
- Pipeline includes early-stage candidates TG-1701 (BTK inhibitor), TG-1801 (CD47xCD19 bispecific), and azer-cel (CAR T) for B-cell disorders and autoimmune diseases [pipeline]
What works
- BRIUMVI has achieved meaningful commercial traction, capturing over one-third of the IV anti-CD20 market and continuing to gain share approaching its fourth full year on the market [news]
- The company holds a strong cash position of $482.6M as of 2026-06-30, providing substantial runway for pipeline development and operations [sec]
- BRIUMVI is being explored in a new indication (treatment-resistant schizophrenia) via a Phase 2 trial initiated in July 2026, potentially expanding its addressable market [news]
What to weigh
- The company's pipeline beyond BRIUMVI is early-stage, with TG-1701, TG-1801, and azer-cel all in Phase 1, and no late-stage pipeline assets to diversify revenue risk [pipeline]
- BRIUMVI faces a competitive landscape with 207 competitors in multiple sclerosis, including established therapies like Ocrevus and numerous Phase 3 programs [pipeline]
- The subcutaneous formulation of ublituximab is still in Phase 3, and its regulatory path (NDA 505b1) is not yet approved, adding uncertainty to future product differentiation [pipeline]
From the filings
Quoted directly from source documents.
BRIUMVI has captured over one-third of the IV anti-CD20 market
“BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market.”
News · September 18, 2026
Catalyst timeline
- 2035-07-16 · Patent_Expiry · ORITAVANCIN DIPHOSPHATE — Patent expiry for oritavancin diphosphate (NDA206334); this is a distant event and not directly related to the company's core marketed product BRIUMVI.
Risks & what to watch (3)›
Key risks
- Over-reliance on BRIUMVI — BRIUMVI is the only approved product; pipeline is early-stage, creating concentration risk [pipeline]
- Competitive MS market — BRIUMVI faces 207 competitors in MS, including established therapies and many Phase 3 programs [pipeline]
- Subcutaneous formulation uncertainty — Subcutaneous ublituximab is still in Phase 3 with NDA 505b1 not yet approved [pipeline]
What to watch
- BRIUMVI market share trajectory in the IV anti-CD20 segment, as it approaches its fourth full year on the market [news]
- Phase 2 results of BRIUMVI in treatment-resistant schizophrenia, initiated July 2026 [news]
- Progress of subcutaneous ublituximab Phase 3 program and NDA 505b1 regulatory submission [pipeline]
- Early clinical data from Phase 1 pipeline candidates TG-1701, TG-1801, and azer-cel [pipeline]
Sources: Catalysts · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run TG THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TG THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.71 · 11% dilution
Lead: Approved
8 candidates
1 upcoming, next in ~3197d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
361
Total value held
$3.44B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 22,252,930 | $739.2M |
| state street corp | 8,649,766 | $287.3M |
| vanguard portfolio management llc | 8,273,979 | $274.9M |
| vanguard capital management llc | 6,603,258 | $219.4M |
| soleus capital management, l.p. | 4,029,319 | $133.9M |
| geode capital management, llc | 3,499,916 | $116.3M |
| clearbridge investments, llc | 3,210,930 | $106.7M |
| goldman sachs group inc | 2,287,688 | $76.0M |
| congress asset management co | 2,168,081 | $72.0M |
| jane street group, llc | 2,041,669 | $67.8M |
Showing top 10 of 361 institutional holders of TG THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 24, 2026- % of float
- 23.7%
- Days to cover
- 13.6
- Shares short
- 28,943,524
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TGTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for TG THERAPEUTICS, INC.?
TG Therapeutics, Inc. (TGTX) is a commercial-stage biopharmaceutical company focused on immunology and oncology, anchored by its approved multiple sclerosis therapy BRIUMVI (ublituximab-xiiy) and supported by a pipeline of early-stage assets.
What is TG THERAPEUTICS, INC.'s lead drug candidate?
TG THERAPEUTICS, INC.'s most advanced tracked candidate is Azer-cel (Phase 1) for B-cell Mediated Autoimmune Disorders.
What is TG THERAPEUTICS, INC.'s next catalyst?
TG THERAPEUTICS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA206334" — expected July 16, 2035.
Who is the CEO of TG THERAPEUTICS, INC.?
Mr. Michael S. Weiss Esq., J.D. is the chief executive officer of TG THERAPEUTICS, INC. (TGTX).
Where is TG THERAPEUTICS, INC. headquartered?
TG THERAPEUTICS, INC. (TGTX) is headquartered in Morrisville, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.